← Eichor
Study identifier: NCT07104539 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Strength Training Response of Muscle in GLP-1 Users

Condition: Muscle Mass  ·  Sponsor: Virginia Polytechnic Institute and State University

PhaseNA
Planned participants30
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersYes

About this study

GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.

This description comes directly from the study's public registry record.

Talk to the study team

Kevin Davy  ·  540-231-3487  ·  kdavy@vt.edu

Elaina Marinik  ·  540-231-0923  ·  emarinik@vt.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Virginia TechBlacksburg, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07104539